Lipella Pharmaceuticals Inc. (LIPO)
Chart Events
Performance Outlook
| Previous Close | 1.9000 |
| Open | 1.8500 |
| Bid | 1.7700 x 1000 |
| Ask | 1.9000 x 2900 |
| Day's Range | 1.7881 - 1.9300 |
| 52 Week Range | 1.7200 - 7.7200 |
| Volume | |
| Avg. Volume | 973,130 |
| Market Cap | 10.271M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association
Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company") today announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis.
- PR Newswire
Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.
- PR Newswire
Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10
Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced top line results of the Company's recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for whi
